Inactivation of the CDKN2A and the p53 tumour suppressor genes in external genital carcinomas and their precursors

British Journal of Dermatology

Volumn 156, Issue 3, 2007, Pages 448-453

  Soufir, N ^a   Queille, S ^b   Liboutet, M ^b   Thibaudeau, O ^b   Bachelier, F ^b   Delestaing, G ^b   Balloy, B C ^b   Breuer, J ^c   Janin, A ^b   Dubertret, L ^b   Vilmer, C ^b   Basset Seguin, N ^b  

^a BICHAT HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

CDKN2A; Genital carcinoma; Human papillomavirus; p53

Indexed keywords

CDKN2A PROTEIN; PROTEIN; PROTEIN P14; PROTEIN P16; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE INACTIVATION; GENE SEQUENCE; GENITAL SYSTEM; GENITAL TRACT CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LICHEN SCLEROSUS ET ATROPHICUS; MALE; METHYLATION; MUTATION; PATHOGENESIS; PENIS CANCER; PRECURSOR; PREVALENCE; PRIORITY JOURNAL; PROTEIN STABILITY; SCREENING; SINGLE STRAND CONFORMATION POLYMORPHISM; STAINING; TUMOR SUPPRESSOR GENE; VULVA CARCINOMA; WART VIRUS;

AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE SILENCING; GENES, P16; GENES, P53; HUMANS; LICHEN SCLEROSUS ET ATROPHICUS; MALE; MIDDLE AGED; PENILE NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PRECANCEROUS CONDITIONS; PROMOTER REGIONS (GENETICS); TUMOR SUPPRESSOR PROTEIN P53; VULVAR LICHEN SCLEROSUS; VULVAR NEOPLASMS;

EID: 33846972607     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07604.x     Document Type: Article

References (35)

1. Hording U, Junge J, Daugaard S et al. Vulvar squamous cell carcinoma and papillomaviruses: indications for two different etiologies. Gynecol Oncol 1994; 52:241-6.
2. Santos M, Montagut C, Mellado B et al. Immunohistochemical staining for p16 and p53 in premalignant and malignant epithelial lesions of the vulva. Int J Gynecol Pathol 2004; 23:206-14.
3. Ridley CM. Nomenclature of non-neoplastic vulval conditions. Br J Dermatol 1986; 115:647-8.
4. Vilmer C, Cavelier-Balloy B, Nogues C et al. Analysis of alterations adjacent to invasive vulvar carcinoma and their relationship with the associated carcinoma: a study of 67 cases. Eur J Gynaecol Oncol 1998; 19:25-31.
5. Lee YY, Wilczynski SP, Chumakov A et al. Carcinoma of the vulva: HPV and p53 mutations. Oncogene 1994; 9:1655-9.
6. Hietanen SH, Kurvinen K, Syrjanen K et al. Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells. Am J Obstet Gynecol 1995; 173:1477-82.
7. Pilotti S, D'Amato L, Della Torre G et al. Papillomavirus, p53 alteration, and primary carcinoma of the vulva. Diagn Mol Pathol 1995; 4:239-48.
8. Castren K, Vahakangas K, Heikkinen E, Ranki A. Absence of p53 mutations in benign and pre-malignant male genital lesions with over-expressed p53 protein. Int J Cancer 1998; 77:674-8.
9. Ngan HY, Cheung AN, Liu SS et al. Abnormal expression or mutation of TP53 and HPV in vulvar cancer. Eur J Cancer 1999; 35:481-4.
10. Gastrell FH, McConnell DT. Human papillomavirus and vulval intra-epithelial neoplasia. Best Pract Res Clin Obstet Gynaecol 2001; 15:769-82.
11. Vanin K, Scurry J, Thorne H et al. Overexpression of wild-type p53 in lichen sclerosus adjacent to human papillomavirus-negative vulvar cancer. J Invest Dermatol 2002; 119:1027-33.
12. Rolfe KJ, MacLean AB, Crow JC et al. TP53 mutations in vulval lichen sclerosus adjacent to squamous cell carcinoma of the vulva. Br J Cancer 2003; 89:2249-53.
13. Leibowitch M, Molinie V. Vulvar dermatoses and intra-epithelial neoplasia. Classification, criticism and suggestions. Ann Pathol 1996; 16:334-42.
14. Larsen CJ. Contribution of the dual coding capacity of the p16INK4a/MTS1/CDKN2 locus to human malignancies. Prog Cell Cycle Res 1997; 3:109-24.
15. Sherr CJ. Principles of tumor suppression. Cell 2004; 116:235-46.
16. Enders GH, Koh J, Missero C et al. p16 inhibition of transformed and primary squamous epithelial cells. Oncogene 1996; 12:1239-45.
17. Loughran O, Clark LJ, Bond J et al. Evidence for the inactivation of multiple replicative lifespan genes in immortal human squamous cell carcinoma keratinocytes. Oncogene 1997; 14:1955-64.
18. Hara E, Smith R, Parry D et al. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 1996; 16:859-67.
19. Dimri GP, Itahana K, Acosta M, Campisi J. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol Cell Biol 2000; 20:273-85.
20. Kamijo T, Zindy F, Roussel MF et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91:649-59.
21. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000; 10:94-9.
22. Daya-Grosjean L, Robert C, Drougard C et al. High mutation frequency in ras genes of skin tumors isolated from DNA repair deficient xeroderma pigmentosum patients. Cancer Res 1993; 53:1625-9.
23. Soufir N, Moles JP, Vilmer C et al. p16 UV mutations in human skin epithelial tumors. Oncogene 1999; 18:5477-81.
24. Soufir N, Daya-Grosjean L, de La Salmoniere P et al. Association between INK4a-ARF and p53 mutations in skin carcinomas of xeroderma pigmentosum patients. J Natl Cancer Inst 2000; 92:1841-7.
25. Herman JG, Graff JR, Myohanen S et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U.S.A. 1996; 93:9821-6.
26. Manos MM, Waldman J, Zhang TY et al. Epidemiology and partial nucleotide sequence of four novel genital human papillomaviruses. J Infect Dis 1994; 170:1096-9.
27. Snijders PJ, van den Brule AJ, Schrijnemakers HF et al. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol 1990; 71:173-81.
28. van den Brule AJ, Snijders PJ, Raaphorst PM et al. General primer polymerase chain reaction in combination with sequence analysis for identification of potentially novel human papillomavirus genotypes in cervical lesions. J Clin Microbiol 1992; 30:1716-21.
29. Rosenthal AN, Hopster D, Ryan A, Jacobs IJ. Immunohistochemical analysis of p53 in vulval intraepithelial neoplasia and vulval squamous cell carcinoma. Br J Cancer 2003; 88:251-6.
30. Basset-Seguin N, Moles JP, Mils V et al. TP53 tumor suppressor gene and skin carcinogenesis. J Invest Dermatol 1994; 103:S102-6.
31. Chan MK, Cheung TH, Chung TK et al. Expression of p16INK4 and retinoblastoma protein Rb in vulvar lesions of Chinese women. Gynecol Oncol 1998; 68:156-61.
32. Lerma E, Esteller M, Herman JG, Prat J. Alterations of the p16/Rb/cyclin-D1 pathway in vulvar carcinoma, vulvar intraepithelial neoplasia, and lichen sclerosus. Hum Pathol 2002; 33:1120-5.
33. Pollock PM, Pearson JV, Hayward NK. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer 1996; 15:77-88.
34. Sharpless NE, Alson S, Chan S et al. p16(INK4a) and p53 deficiency cooperate in tumorigenesis. Cancer Res 2002; 62:2761-5.
35. Esteller M, Cordon-Cardo C, Corn PG et al. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 2001; 61:2816-21.